Next-Generation Curcumin-Based NK3 Receptor Antagonists for Personalized Neurokinin-3 Mediated Disorder Treatment

This inventive concept envisions a paradigm shift in NK3 receptor antagonism by leveraging cutting-edge formulations, wearable devices, and biomarker analysis to provide personalized, controlled-release, and targeted treatments for neurokinin-3 mediated disorders.

The original patent disclosed a combination composition of curcumin, green tea extract, and phycocyanin for NK3 receptor antagonism. However, this composition has limitations in terms of release kinetics, bioavailability, and personalized dosing. The new inventive concept addresses these limitations by introducing novel formulations, wearable devices, and biomarker analysis to provide a more effective and targeted treatment approach.

The new inventive concept comprises four key components: 1) a controlled-release curcumin formulation for oral administration, 2) a wearable device for monitoring neurokinin-3 receptor activity, 3) a curcumin-based pharmaceutical composition for transdermal administration, and 4) a biomarker analysis method for predicting treatment efficacy. The controlled-release formulation utilizes a pH-dependent release modifier to delay curcumin release until it reaches the small intestine, ensuring optimal bioavailability. The wearable device monitors neurokinin-3 receptor activity and triggers the release of a customized dose of curcumin from a dispenser. The transdermal composition employs a curcumin-loaded microemulsion and a permeation enhancer to increase curcumin flux across the skin. The biomarker analysis method involves analyzing a biomarker profile comprising neurokinin-B, substance P, and calcitonin gene-related peptide to predict treatment efficacy.

The new claims introduce a novel combination of controlled-release formulations, wearable devices, and biomarker analysis, which are not obvious from the original patent. The inventive step lies in the integration of these components to provide a personalized, targeted, and effective treatment approach for neurokinin-3 mediated disorders.

Alternative embodiments of the inventive concept could include the use of different formulations, such as nanoparticles or liposomes, or the integration of artificial intelligence algorithms to optimize treatment dosing and timing. Variations could also include the use of different biomarkers or the development of implantable devices for continuous curcumin release.

The inventive concept has significant commercial potential in the treatment of neurokinin-3 mediated disorders, such as migraines, depression, and anxiety. The market for NK3 receptor antagonists is expected to grow significantly in the coming years, and this inventive concept is well-positioned to capture a significant share of this market.